Diagnostics are no longer static lab results, they are real-time signals that enable earlier, more precise clinical decisions.
With the rapid growth of genetic testing, biomarkers, and advanced diagnostics, healthcare organizations can better predict disease risk, guide treatment selection, and reduce costly trial-and-error, improving outcomes while lowering unnecessary costs. In this article, Avalon CEO Dr. Bill Kerr, MD, explores the shift toward diagnostic intelligence across the industry and how it will define the future of value-based care
Read the full article at Healthcare IT News.
